Schultes Birgit C
- SEC CIK
- 0002051419
In the past year, 2 open-market sale filings worth $78.9K and no purchases.
Current role at each company
- NTLA Intellia Therapeutics, Inc.EVP, Chief Scientific Officeras of Mar 3, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $78.9K
- 2 filings
- Net
- −$78.9K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Schultes Birgit C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Schultes Birgit CEVP, Chief Scientific Officer | SSale | −8.51K | $9.21 | −$78.4K | −7.9%98.5K after | |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Schultes Birgit CEVP, Chief Scientific Officer | SSale | −31 | $17.38 | −$538.78 | 0.0%105.2K after |